Plain-English translation of NCT03192462 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Pancreatic cancer research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial tested TAA-Specific Cytotoxic T Lymphocytes, which are immune cells grown in a lab from a patient's own blood and designed to recognize and attack pancreatic cancer cells. Researchers gave these cells back to patients through an IV infusion to see if this approach could help control their cancer. The trial examined whether this treatment worked safely in people with different stages of pancreatic cancer.
Standard chemotherapy treatments for pancreatic cancer help some patients, but many still experience disease progression or cannot tolerate standard drugs. This trial was designed to explore whether a personalized immune therapy could offer a new option for patients who needed additional treatment or could not receive conventional chemotherapy.
Participants provided a blood sample, which was sent to a lab to grow specialized immune cells over 1–2 months. Once the cells were ready, participants returned for six infusions given one month apart, each lasting 1–10 minutes through an IV line. Before and after each infusion, participants underwent blood tests and imaging scans to check their tumor and monitor for side effects. Additional blood samples were collected at multiple timepoints over the year following their last infusion to track how the treatment was working.
AI-generated summary from trial data · Oct 11, 2026 · Not medical advice
United States